ArticleScience advances2022
Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Targeting p53 pathways: mechanisms, structures, and advances in therapy.Signal transduction and targeted therapy · 2023Pooled it
- Spatiotemporal dynamics of the host-tumor metabolic interface: Implications for precision nutritional oncology.Genes & diseases · 2026Review
- Metabolites and cancer metastasis.Oncogene · 2026Review
- Integrated transcriptomic and in silico structural analysis identifies NFS1 and HSPA9 as potential regulators associated with mitochondrial ferroptosis and cell death resistance in colorectal cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Seipin modulates Alzheimer's disease pathogenesis by regulating ferroptosis through a glycine-mediated metabolic pathway.Metabolic brain disease · 2026Article
- L-2-Hydroxyglutarate sensitizes ferroptosis through ATF3/CHAC1-mediated glutathione degradation in hepatocellular carcinoma.Cell death & disease · 2026Article
- Fundamentals and emerging frontiers in p53-targeted drug development.Biochemistry and biophysics reports · 2026Review
- Wild-Type p53 Protein Enhances APR-246-Induced Cytotoxicity in Acute Myeloid Leukemia and Normal Hematopoietic Stem/Progenitor Cells.International journal of molecular sciences · 2026Article
- Unbiased assessment of APR-246 responsive p53 mutants in ovarian cancer.Cell death discovery · 2026Article
- Potential diagnostic, prognostic, and therapeutic implications of ferroptosis in myelodysplastic syndromes.Discover oncology · 2026Review
- Pirfenidone Sensitizes Hepatic Stellate Cells to Ferroptosis by Reprogramming Glutamine and Serine Metabolism for GSH Depletion.Antioxidants (Basel, Switzerland) · 2026Article
- Regulatory networks of iron sulfur cluster biology in cancer mechanisms and therapeutic perspectives.iScience · 2026Review
- Redox cycling nitroxide limits cellular iron availability and selectively inhibits iron-sulfur cluster metabolism.Cell death discovery · 2026Article
- APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.Scientific reports · 2026Article
- Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy.bioRxiv : the preprint server for biology · 2026Article
- Iron and metabolic rewiring in cancer.Oncogenesis · 2026Review
- A five-gene mitochondria-associated prognostic signature for bladder cancer.International journal of clinical and experimental pathology · 2026Article
- The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes.Frontiers in oncology · 2026Review
- Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions.Frontiers in pharmacology · 2026Review
- Mitochondrial convergence of ferroptosis and cuproptosis in castration-resistant prostate cancer: From metabolic vulnerabilities to therapeutic targeting.BBA advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 5 institutions in 3 countries.
Kenji M FujiharaGastrointestinal Cancer Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-8387-4912
Bonnie Z ZhangGastrointestinal Cancer Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Thomas D JacksonDepartment of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-4864-496X
Moses O OgunkolaInstitute of Biochemistry and Biology Department for Molecular Enzymology, University of Potsdam, Potsdam, Germany.ORCID 0000-0002-2993-7564
Brunda NijagalMetabolomics Australia, The Bio21 Institute of Molecular Science and Biotechnology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0001-9853-7866
Julia V MilneGastrointestinal Cancer Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-8503-9304
David A SallmanMalignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0003-0504-8233
Ching-Seng AngBio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0001-7861-6719
Iva NikolicVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Conor J KearneySir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-9891-5078
Simon J HoggSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-3170-839X
Carlos S CabalagGastrointestinal Cancer Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Vivien R SuttonSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-3156-7355
Sally WattSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Asuka T FujiharaGastrointestinal Cancer Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-5262-8690
Joseph A TrapaniSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-0983-1532
Kaylene J SimpsonSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0001-9136-1781
Diana StojanovskiDepartment of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria, Australia.
Silke LeimkühlerInstitute of Biochemistry and Biology Department for Molecular Enzymology, University of Potsdam, Potsdam, Germany.ORCID 0000-0003-3238-2122
Sue HauptSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-2484-1712
Wayne A PhillipsGastrointestinal Cancer Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-7961-638X
Nicholas J ClemonsGastrointestinal Cancer Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-9283-9978
The University of Melbourne · AUPeter MacCallum Cancer Centre · AUUniversity of Potsdam · DEMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
The mechanism of action of eprenetapopt (APR-246, PRIMA-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.